Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Therapeutic strategies for graft-versus-host disease in the new era.

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMasako Toyosaki

Discussion

Loading...

Member takes

Overview

Overview of therapeutic strategies and biomarkers for acute and chronic gvhd, highlighting recent developments.

Key Points

  • Graft-versus-host disease remains a major cause of mortality post-transplantation, with 40-60% of patients suffering from acute gvhd.
  • Recent advancements in biomarkers and risk stratification strategies have enabled better management of acute gvhd and chronic gvhd.
  • A new severity classification system for acute gvhd could improve preemptive treatment strategies for patients undergoing transplants.
  • Three new drugs have been approved for the treatment of chronic gvhd, marking significant progress in therapeutic options.

Cite This Study

Masako Toyosaki (2025) studied this question.

synapsesocial.com/papers/68c1bb7854b1d3bfb60eddafhttps://doi.org/10.11406/rinketsu.66.635
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation2024
  2. 2Biochemical markers and emerging therapies for intestinal manifestation of graft-versus-host disease2025 · 2 citations
  3. 3New molecules in the therapy of chronic graft-versus-host disease.2025 · 3 citations
  4. 4Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?2024 · 9 citations
  5. 5Chronic Graft-Versus-Host Disease: A Review of Current Treatments Beyond Second-Line and Emerging Therapies2026